A 12-Month Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Patients With Partial Lipodystrophy

Protocol No
ENDO-AMRYT-APG-20
Phase
III
Summary

This project is being done to see whether a medication called metreleptin, also known as the study medication/treatment, is safe and works in patients with familial partial lipodystrophy (FPLD).

Description
Daily Subcutaneous Metreleptin Treatment in Patients With FPLD
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL